New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
08:11 EDTAMPEAmpio closes enrollment in OptimEyes study for presentation to FDA
Ampio Pharmaceuticals has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema - oral treatment with Optina. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation. By reducing the patient sample size, the company expects data by Q4.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:04 EDTAMPEAmpio subsidiary secures European distribution for RedoxSYS diagnostic system
Ampio subsidiary Luoxis Diagnostics has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS Diagnostic System to academic and pharma-based research centers within their respective territories. RedoxSYS is a diagnostic platform and robust research tool capable of measuring oxidation-reduction potential in the body in response to injury, illness, or stress. Eurobio was granted territorial rights to offer RedoxSYS to institutions based in France and Switzerland, while Una Health Limited and THP Medical were granted territorial rights to the U.K. and Austria, respectively. These are multi-year agreements with the option to renew at the 3-5 year mark.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use